Gregg Keaney, PhD2018-12-06T15:07:16+00:00

Gregg Keaney, PhD

Vice President of Product Development

Gregg Keaney is the Vice President of Product Development at Cadent Therapeutics and leads CMC (Chemistry, Manufacturing, and Controls) development, Phase 1 clinical operations, and a broad range of interdisciplinary portfolio management activities.  At Ataxion Therapeutics, Gregg led the medicinal chemistry program and managed its fully-externalized drug discovery model of more than twenty worldwide collaborators.  Preceding Ataxion, Gregg was one of the very first employees at H3 Biomedicine and headed its drug discovery program on natural product-based splicing modulators into clinical development.  His industrial career of scientific entrepreneurship at biotech startup companies began at Infinity Pharmaceuticals where he advanced oncology-focused programs in medicinal and process chemistry capacities.

Gregg obtained his Ph.D. in synthetic organic chemistry from Yale University and has served as an elected board member of the Yale Graduate School Alumni Association Executive Committee.  His work has been profiled in the alumni magazines of Yale University and Tufts University, and in 2015, he received the American Chemical Society’s Young Industrial Investigator Award.

Our Team

Gregg Keaney, PhD

Vice President of Product Development

Gregg Keaney is the Vice President of Product Development at Cadent Therapeutics and leads CMC (Chemistry, Manufacturing, and Controls) development, Phase 1 clinical operations, and a broad range of interdisciplinary portfolio management activities.  At Ataxion Therapeutics, Gregg led the medicinal chemistry program and managed its fully-externalized drug discovery model of more than twenty worldwide collaborators.  Preceding Ataxion, Gregg was one of the very first employees at H3 Biomedicine and headed its drug discovery program on natural product-based splicing modulators into clinical development.  His industrial career of scientific entrepreneurship at biotech startup companies began at Infinity Pharmaceuticals where he advanced oncology-focused programs in medicinal and process chemistry capacities.

Gregg obtained his Ph.D. in synthetic organic chemistry from Yale University and has served as an elected board member of the Yale Graduate School Alumni Association Executive Committee.  His work has been profiled in the alumni magazines of Yale University and Tufts University, and in 2015, he received the American Chemical Society’s Young Industrial Investigator Award.

Our Team

Gregg Keaney, PhD

Vice President of Product Development

Gregg Keaney is the Vice President of Product Development at Cadent Therapeutics and leads CMC (Chemistry, Manufacturing, and Controls) development, Phase 1 clinical operations, and a broad range of interdisciplinary portfolio management activities.  At Ataxion Therapeutics, Gregg led the medicinal chemistry program and managed its fully-externalized drug discovery model of more than twenty worldwide collaborators.  Preceding Ataxion, Gregg was one of the very first employees at H3 Biomedicine and headed its drug discovery program on natural product-based splicing modulators into clinical development.  His industrial career of scientific entrepreneurship at biotech startup companies began at Infinity Pharmaceuticals where he advanced oncology-focused programs in medicinal and process chemistry capacities.

Gregg obtained his Ph.D. in synthetic organic chemistry from Yale University and has served as an elected board member of the Yale Graduate School Alumni Association Executive Committee.  His work has been profiled in the alumni magazines of Yale University and Tufts University, and in 2015, he received the American Chemical Society’s Young Industrial Investigator Award.

Our Team